Page 53 - 202002

criteria from the American Diabetes [9] 杨婷, 李明莎, 王治坤. 皮下注射索

Association: national cross sectional 马鲁肽治疗2型糖尿病有效性和安全性的
study [J]. BMJ, 2020,369:m997. Meta 分 析 [J]. 中 国 药 房 , 2018, 29(20):

[3] 中华医学会糖尿病学分会. 中国2型 2856-2861.
糖尿病防治指南(2017年版) [J]. 中华糖尿 [10] 张新丽, 丁发明, 尹茂山. 新型胰高

病杂志, 2018, 10(1): 4-67. 血糖素样肽-1类似物-索马鲁肽 [J]. 中国临
床药理学杂志, 2018, 34(20): 2456-2460.
[4] MUSKIET MHA, TONNEIJCK L,

SMITS MM, et al. GLP-1 and the kidney: [11] 林旋, 王俊玲, 李泰明, 等. 长效胰
from physiology to pharmacology and 高血糖素样肽-1受体激动剂的研究进展 [J].
outcomes in diabetes [J]. Nat Rev 中国新药杂志, 2015, 24(15): 1735-1741.

Nephrol, 2017,13(10):605-628.
[12] 张恩景, 李玉萍. 长效胰高血糖素
[5] SPOSITO AC, BERWANGER O, 样肽-1受体激动剂索马鲁肽 [J]. 中南药学,
DE CARVALHO LSF, et al. GLP-1RAs in 2018, 16(6): 817-820.

type 2 diabetes: mechanisms that [13] LINGVAY I, CATARIG AM,
underlie cardiovascular effects and FRIAS JP, et al. Efficacy and safety of
overview of cardiovascular outcome data once-weekly semaglutide versus daily

[J]. Cardiovasc Diabetol,2018,17(1):157.
canagliflozin as add-on to metformin in
[6] LAU J, BLOCH P, SCHÄFFER L, patients with type 2 diabetes (SUSTAIN
et al. Discovery of the Once-Weekly 8): a double-blind, phase 3b, randomised

Glucagon-Like Peptide-1 (GLP-1) controlled trial [J]. Lancet Diabetes
Analogue Semaglutide [J]. J Med Chem, Endocrinol, 2019,7(11):834-844.
2015,58(18):7370-7380.
[14] ZINMAN B, BHOSEKAR V,

[7] NAUCK MA, MEIER JJ, BUSCH R, et al. Semaglutide once
CAVENDER MA, et al. Cardiovascular weekly as add-on to SGLT-2 inhibitor
Actions and Clinical Outcomes With therapy in type 2 diabetes (SUSTAIN 9): a

Glucagon-Like Peptide-1 Receptor randomised, placebo-controlled trial [J].
Agonists and Dipeptidyl Peptidase-4 Lancet Diabetes Endocrinol,
Inhibitors [J]. Circulation, 2019,7(5):356-367.

2017,136(9):849-870.
[15] CAPEHORN MS, CATARIG AM,
[8] HALL S, ISAACS D, CLEMENTS FURBERG JK, et al. Efficacy and safety
JN. Pharmacokinetics and Clinical of once-weekly semaglutide 1.0 mg vs

Implications of Semaglutide: A New once-daily liraglutide 1.2 mg as add-on to
Glucagon-Like Peptide (GLP)-1 Receptor 1-3 oral antidiabetic drugs in subjects with
Agonist [J]. Clin Pharmacokinet, type 2 diabetes (SUSTAIN 10) [J].

2018,57(12):1529-1538. Diabetes Metab, 2020,46(2):100-109.

ć͆ḤḤc